Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
24 hedge funds and large institutions have $2.18M invested in Iterum Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
33% more funds holding
Funds holding: 18 → 24 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $2.22M → $2.18M (-$48.5K)
4.51% less ownership
Funds ownership: 8.99% → 4.48% (-4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$688K |
| 2 |
CFD
Creative Financial Designs
Kokomo,
Indiana
|
+$93.9K |
| 3 |
AF
Apollon Financial
Mount Pleasant,
South Carolina
|
+$40K |
| 4 |
Two Sigma Investments
New York
|
+$39.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$33.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.46M |
| 2 |
AGM
Alpine Global Management
New York
|
-$78.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$16.3K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$2 |
ITRM Hedge Fund Activity: Q4 2024 in Review
24 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q4 2024, worth a combined $2.18M — down 2.2% from $2.22M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ITRM positions and 5 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $688K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.46M sold.
- 24 institutional investors held Iterum Therapeutics (ITRM) as of Q4 2024, up from 18 in Q3 2024.
- Funds reported $2.18M of Iterum Therapeutics stock for Q4 2024, down 2.2% quarter-over-quarter.
- 12 funds opened new Iterum Therapeutics positions in Q4 2024 and 5 closed out, a net change of +7 holders.
- The largest Iterum Therapeutics buyer in Q4 2024 was Renaissance Technologies, an estimated $688K added.
- The largest Iterum Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2024.